FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
59.931,98 +1.566,46 (+2,68%)
OptiNose, Inc. (OPTN)
Dopo ore:
| Chiusura precedente | 0,9277 |
| Aperto | 0,9327 |
| Denaro | 0,8655 x 200 |
| Lettera | 0,9243 x 200 |
| Min-Max giorno | 0,8942 - 0,9655 |
| Intervallo di 52 settimane | 0,8940 - 2,1000 |
| Volume | |
| Media Volume | 585.225 |
| Capitalizzazione | 100,733M |
| Beta (5 anni mensile) | -0,24 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3200 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 3,75 |
GlobeNewswireOptinose to Present at the 2023 Cantor Global Healthcare Conference
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcas
- GlobeNewswire
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023 as SG&A and R&D expenses decreased by $22M or 33% compared to first half 2022 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT
- GlobeNewswire
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 YARDLEY, Pa., July 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $19.5 million for the three months ended June 30, 2023.
